Impact of Chlordecone on Active Chronic Hepatitis
Ключавыя словы
Рэферат
Апісанне
Actually, there is no data concerning the impact of chlordecone on the evolution of fibrosis to cirrhosis in chronic hepatitis whereas many studies have been reported liver damage in mice. The goal of this study is to know if co-exposition to chlordecone can induce evolution to cirrhosis in chronic hepatitis due to alcohol or viral hepatitis. At first, we will assess a group of patients with chronic hepatitis B, C or due to alcohol without fibrosis. And they will be compared to patients with cirrhosis exposed to chlordecone too. Patients will be included in 2 hospital centers. All these patients should have an active liver disease. The activity will be defined by histology or elevated transaminases (>2N), fibrosis will be defined by histology or an association of fibroscan and biological markers. Exposition to chlordecone will be evaluated by a blood chlordecone measure for every patient.
Даты
| Апошняя праверка: | 11/30/2017 |
| Упершыню прадстаўлена: | 12/03/2017 |
| Меркаваная колькасць заявак прадстаўлена: | 12/07/2017 |
| Першае паведамленне: | 12/13/2017 |
| Апошняе абнаўленне адпраўлена: | 12/07/2017 |
| Апошняе абнаўленне апублікавана: | 12/13/2017 |
| Фактычная дата пачатку даследавання: | 11/07/2011 |
| Разліковая дата першаснага завяршэння: | 12/20/2015 |
| Разліковая дата завяршэння даследавання: | 12/20/2015 |
Стан альбо хвароба
Ўмяшанне / лячэнне
Diagnostic Test: Blood samples
Фаза
Групы ўзбраенняў
| Рука | Ўмяшанне / лячэнне |
|---|---|
| Other: Case group with Metavir score between F1 and F4 Patient with Metavir score between F1 and F4 will be assigned to the case group. Collected data will contain epidemiological and biological data, blood samples with chlordecone dosage. | |
| Other: Control group with Metavir score of between F0 Patient with Metavir score of F0 will be assigned to the control group. Collected data will contain epidemiological and biological data. Blood samples with chlordecone dosage will be performed. |
Крытэрыі прыдатнасці
| Узрост, які мае права на вучобу | 18 Years Каб 18 Years |
| Пол, прыдатны для навучання | All |
| Прымае здаровых валанцёраў | Так |
| Крытэрыі | Inclusion Criteria: - Age above 18 years - Active chronic hepatitis B or C or alcoholic - Patient without previous antiviral therapy, activity confirmed by histology or elevated transaminases - Alcohol consumption more than 20g/d for women and 30g/d for men responsible of chronic alcoholic disease - Seronegative HIV status, inform consent signed, health insurance Exclusion Criteria: - Inactive chronic hepatitis - Other chronic hepatitis as auto-immune hepatitis, hemochromatosis, wilson disease, acute hepatitis due to medication, transplantation, antiviral or imunosupressive treatment, psychiatric disease - Co-infection with HIV, HBV or HCV - Pregnancy |
Вынік
Першасныя вынікі
1. Evaluation of progression to cirrhosis with a correlation test between chlordecone exposure and fibrosis in active and chronic hepatitis due to virus B, C or alcohol. [through study completion, an average of 5 years.]
Меры другаснага выніку
1. Epidemiological study of hepatitis B, C and alcoholic in Guadeloupe [through study completion, an average of 5 years.]
